Major and durable responses to photon and electron-beam palliative radiotherapies after immune-checkpoint inhibitors in head and neck cancer

被引：1
|
作者：
Cabezas-Camarero, Santiago [1 ,3 ]
Masedo, Gonzalo V. azquez [2 ]
Puebla-Diaz, Fernando [2 ]
Corona, Juan Antonio [2 ]
Perez-Seguraa, Pedro [1 ]
机构：
[1] Hosp Clin Univ San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Head & Neck Canc Neurooncol & Familiar Canc Unit, Madrid, Spain
[2] Hosp Clin Univ San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Dept Radiat Oncol, Madrid, Spain
[3] Hosp Clin Univ San Carlos, Inst Invest Sanitaria San Carlos IdISSC, Med Oncol Dept, Madrid, Spain
来源：
ORAL ONCOLOGY | 2024年 / 150卷
关键词：
Head and neck cancer; Radiotherapy; Electron beam radiotherapy; Photon beam radiotherapy; Immunotherapy; PDL1; Durvalumab; SQUAMOUS-CELL CARCINOMA; CETUXIMAB; RECURRENT; PHASE; CARE;
D O I：
10.1016/j.oraloncology.2024.106719
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The immuno-modulatory effects of ionizing radiation are well-known and preclinical studies suggest a synergistic effect of combining radiotherapy (RT) and IO. However, data regarding the clinical activity and safety of this approach are limited. Methods: We present the cases of two patients with SCCHN primary progressing to PDL1-based IO within a clinical trial (NCT03383094), that received subsequent but not concurrent palliative RT using two different modalities (electron beam and photon beam therapies). Results: Both patients achieved major and durable responses at 4 irradiated sites, with excellent tolerance and no grade >= 3 toxicities. Complete response occurred in 3 of the disease areas (all locoregional) and partial response in 1 metastatic lesion. Conclusion: Palliative radiotherapy after progression to IO was safe and demonstrated profound and durable responses in the cases presented.
引用
收藏
页数：4
相关论文
共 40 条
  • [1] Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer
    Upadhyay, Rituraj
    Gogineni, Emile
    Tocaj, Glenis
    Ma, Sung J.
    Bonomi, Marcelo
    Bhateja, Priyanka
    Konieczkowski, David J.
    Baliga, Sujith
    Mitchell, Darrion L.
    Jhawar, Sachin R.
    Zhu, Simeng
    Grecula, John C.
    Dibs, Khaled
    Gamez, Mauricio E.
    Blakaj, Dukagjin M.
    CANCERS, 2024, 16 (05)
  • [2] Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis
    Tang, Lingrong
    Liu, Tingting
    Chen, Jun
    Dang, Jun
    Li, Guang
    IMMUNOTHERAPY, 2021, 13 (06) : 541 - 555
  • [3] Efficacy of Chemotherapy After Immune Checkpoint Inhibitor Discontinuation in Head and Neck Cancer
    Fukuoka, Osamu
    Saito, Yuki
    Mukai, Toshiyuki
    Hayashi, Takaaki
    Yamamura, Koji
    Sakai, Toshihiko
    Kobayashi, Kenya
    Akashi, Ken
    Yoshida, Masafumi
    Ando, Mizuo
    Yamasoba, Tatsuya
    LARYNGOSCOPE, 2024, 134 (01): : 228 - 235
  • [4] Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer
    Chung, Chih-Hung
    Lin, Chun-Yu
    Chen, Chih-Yu
    Hsueh, Chun-Wei
    Chang, Yao-Wen
    Wang, Chen-Chi
    Chu, Pen-Yuan
    Tai, Shyh-Kuan
    Yang, Muh-Hwa
    ADVANCED SCIENCE, 2023, 10 (15)
  • [5] Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer
    Doumas, Stergios
    Foukas, Periklis G.
    Economopoulou, Panagiota
    Kotsantis, Ioannis
    Psyrri, Amanda
    ORAL ONCOLOGY, 2020, 100
  • [6] Adverse jaw outcomes from immune checkpoint inhibitors for head and neck cancer? Case reports
    Subramanian, Gayathri
    Yeung, Vincent
    Baredes, Soly
    Kim, Sung
    Bergsbaken, Tessa
    Quek, Samuel Y. P.
    QUINTESSENCE INTERNATIONAL, 2024, 55 (03): : 244 - 249
  • [7] Cardiovascular events after cancer immunotherapy as oncologic emergencies: Analyses of 610 head and neck cancer patients treated with immune checkpoint inhibitors
    Reyes-Gibby, Cielito C.
    Qdaisat, Aiham
    Ferrarotto, Renata
    Fadol, Anecita
    Bischof, Jason J.
    Coyne, Christopher J.
    Lipe, Demis N.
    Hanna, Ehab Y.
    Shete, Sanjay
    Abe, Jun-Ichi
    Yeung, Sai-Ching J.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2024, 46 (03): : 627 - 635
  • [8] Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors
    Lai, Cheng-Lun
    Chen, Tien-Hua
    Chang, Peter Mu-Hsin
    Tai, Shyh-Kuan
    Chu, Pen-Yuan
    Yang, Muh-Hwa
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2022, 85 (06) : 687 - 692
  • [9] Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
    Kansal, Vikash
    Burnham, Andre J.
    Kinney, Brendan L. C.
    Saba, Nabil
    Paulos, Chrystal
    Lesinski, Gregory B.
    Buchwald, Zachary S.
    Schmitt, Nicole C.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)
  • [10] Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study
    Bersanelli, Melissa
    Lattanzi, Elisabetta
    D'Abbiero, Nunziata
    Buti, Sebastiano
    Leonetti, Alessandro
    Cane, Maria Giulia
    Trapani, Salvatore
    Gravina, Giovanni Luca
    Porzio, Giampiero
    Cannita, Katia
    Di Marino, Pietro
    Grassadonia, Antonino
    Tinari, Nicola
    De Tursi, Michele
    Giaiacopi, Elisa
    Michiara, Maria
    Bordi, Paola
    Perrone, Fabiana
    Caravatta, Luciana
    Trignani, Marianna
    Genovesi, Domenico
    Natoli, Clara
    Ficorella, Corrado
    Tiseo, Marcello
    Cortellini, Alessio
    BIOMEDICAL REPORTS, 2020, 12 (02) : 59 - 67
1234